Bon Natural Life Ltd SEC Filings

Bon Natural Life Limited announced a finance leadership transition. Wallace Lee notified the company of his resignation as Chief Financial Officer, effective November 14, 2025. The company stated there was no known disagreement with Mr. Lee on operations, policies, or practices.

Effective November 12, 2025, Ma Xin was appointed as the new Chief Financial Officer. The company entered into an employment agreement with Mr. Ma that becomes effective November 17, 2025, providing a monthly salary of RMB35,000 (approximately US$4,900). Mr. Ma previously held senior finance roles, including CFO positions at several China-based companies and finance leadership at Zhejiang United Hydrogen Energy Technology. He holds MSc degrees in Finance and Management from the University of Leicester and credentials as a Washington State CPA and a CFA charterholder.

Bon Natural Life Limited filed an amended F-3 shelf to register up to $500,000,000 of Class A ordinary shares, debt securities, warrants, rights, and units, to be offered from time to time after effectiveness.

The company notes General Instruction I.B.5 limits any single public primary offering to no more than one-third of public float while below $75 million. As of October 14, 2025, public float was approximately $13,878,293.88 based on a $2.28 last sale price. The Ordinary Shares trade on Nasdaq under “BON”.

The filing highlights China-related considerations: Bon Natural Life is a Cayman holding company operating through PRC subsidiaries; PRC policy changes could materially affect operations. The company references the HFCAA; its auditor, YCM CPA INC., is U.S.-based and PCAOB-registered. As an existing issuer under the CSRC Overseas Listing Trial Measures, future securities offerings would require a filing with the CSRC. The company states the Cybersecurity Review Measures would apply to online platform operators with at least one million users’ personal information; it does not meet that threshold and reports no related inquiries.

Bon Natural Life Limited filed a Form F-3 shelf registration to offer, from time to time after effectiveness, up to $500,000,000 of Class A ordinary shares, debt securities, warrants, rights, and units, including securities convertible or exchangeable into those classes. Any specific terms and sale methods will be set in a future prospectus supplement.

The Ordinary Shares trade on Nasdaq as BON. On October 14, 2025, the last reported sale price was $2.28 per share, and the public float was approximately $13,878,293.88. Under Form F-3 General Instruction I.B.5, the company will not sell, in primary offerings, more than one‑third of its public float in any 12‑month period while float remains below $75 million; the company states it has not sold securities under I.B.5 in the prior 12 months.

Sales may occur at fixed, market, or negotiated prices, to or through underwriters, directly to purchasers, through agents, or combinations thereof. The filing highlights risks tied to operating in China, including evolving PRC oversight and the HFCAA. The auditor for the year ended September 30, 2024 is YCM CPA INC., a U.S.-based PCAOB‑registered firm.

Bon Natural Life Limited reported unaudited condensed consolidated results for the six months ended March 31, 2025, showing a large increase in cash and meaningful financing inflows. Cash at period end was reported as $8,894,053, up from beginning balances shown as $657,205 and $112,751 in the provided table, with a net increase in cash of $8,236,848. Net cash provided by financing activities is reported as $12,322,244, while net cash provided by (used in) investing activities is $4,359.

On the expense side, general and administrative expenses are shown as $1,459,009 representing 18.4% of revenues, and interest expense, net is $(164,468) (2.1%). Selling expenses are shown as $(68,317) (0.9%). The company reports a foreign currency exchange gain of $79,748 in the period. The filing excerpt contains fragmented line items and comparative columns; all figures above are taken directly from the provided content.

Bon Natural Life Limited (Nasdaq: BON) filed a Form 6-K announcing that the Nasdaq Hearings Panel has granted continued listing status after the company rectified its minimum bid price deficiency cited in May 2025.

Highlights

• Compliance regained: On 2 July 2025 the Panel confirmed BON now meets Listing Rule 5550(a)(2) (US$1.00 minimum bid price).
• Ongoing oversight: Nasdaq imposed a one-year Discretionary Panel Monitor to track future compliance and public-interest matters.
• Dilution spotlight: The March 2025 financing issued 101,250,968 Class A shares; warrants could add 8,333,332 more (total potential 116,666,648), triggering Nasdaq concerns.
• Mitigation steps: Management is negotiating amendments with March investors, has launched a share-repurchase program, and pledges to avoid “overly complex or inherently dilutive” instruments in future.
• Governance & controls: BON will enhance board independence, introduce mandatory pre-issuance checklists, assign dedicated Nasdaq-compliance staff, provide regular training, and retain external legal/compliance advisers.

No financial or earnings data were provided. The filing primarily reassures investors that the U.S. listing is intact while acknowledging dilution risks and outlining governance reforms to rebuild market confidence.